Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

BioNTech SE's $11.1B oncology move signals potential, but clinical hurdles remain. Click for my look at the BNTX deal with ...

BioNTech and Bristol Myers Squibb have agreed to jointly develop and commercialize BioNTech’s BNT327 cancer-drug candidate in ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

BioNTech (NASDAQ:BNTX – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

By Michael Erman and Ludwig Burger (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's ...

Princeton: BioNTech SE and Bristol Myers Squibb have announced that the companies have entered into an agreement for the ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.